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Abstract
Background: Photodynamic therapy (PDT) uses the combination of photosensitizing drugs and harmless light to cause
selective damage to tumor cells. PDT is therefore an option for focal therapy of localized disease or for otherwise
unresectable tumors. In addition, there is increasing evidence that PDT can induce systemic anti-tumor immunity,
supporting control of tumor cells, which were not eliminated by the primary treatment. However, the effect of non-lethal
PDT on the behavior and malignant potential of tumor cells surviving PDT is molecularly not well defined.
Methodology/Principal Findings: Here we have evaluated changes in the transcriptome of human glioblastoma (U87,
U373) and human (PC-3, DU145) and murine prostate cancer cells (TRAMP-C1, TRAMP-C2) after non-lethal PDT in vitro and in
vivo using oligonucleotide microarray analyses. We found that the overall response was similar between the different cell
lines and photosensitizers both in vitro and in vivo. The most prominently upregulated genes encoded proteins that belong
to pathways activated by cellular stress or are involved in cell cycle arrest. This response was similar to the rescue response
of tumor cells following high-dose PDT. In contrast, tumor cells dealing with non-lethal PDT were found to significantly
upregulate a number of immune genes, which included the chemokine genes CXCL2, CXCL3 and IL8/CXCL8 as well as the
genes for IL6 and its receptor IL6R, which can stimulate proinflammatory reactions, while IL6 and IL6R can also enhance
tumor growth.
Conclusions: Our results indicate that PDT can support anti-tumor immune responses and is, therefore, a rational therapy
even if tumor cells cannot be completely eliminated by primary phototoxic mechanisms alone. However, non-lethal PDT can
also stimulate tumor growth-promoting autocrine loops, as seen by the upregulation of IL6 and its receptor. Thus the
efficacy of PDT to treat tumors may be improved by controlling unwanted and potentially deleterious growth-stimulatory
pathways.
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Introduction
Photodynamic therapy (PDT) in oncology is based on the
selective accumulation of a photosensitizer (PS) in cancer cells,
followed by its activation by low-energy tissue-penetrating light. In
the presence of oxygen, the excited PS produces reactive oxygen
species (ROS) such as singlet oxygen, which are toxic for living
cells [1].
Various PS exist which all have their advantages and their
limitations. 5-Amino-levulinic acid (5-ALA) is a natural precursor
for heme in mammalian cells. Cells metabolize 5-ALA to heme,
producing protoporphyrin IX (PpIX) as an intermediate product
in their mitochondria. Because conversion of PpIX to heme is a
rate limiting step, PpIX accumulates in cancer cells as a result of
preferential uptake and retention of 5-ALA. PpIX localizes
intracellularly to mitochondria and to the cytoplasm [2].
PhotofrinH, on the other hand, is an exogenous photosensitizer
which also accumulates in cancer cells but is located at various
cellular membranes [3]. In general, activation of PS which target
mitochondria lead to cancer cell apoptosis, while PS that associate
with cell membranes predominantly induce cell necrosis [2].
Originally, the goal of PDT in oncology was to completely
eliminate localized tumors. However, the clinical application of
PDT in the treatment of cancer has now begun to change.
Recently, treatment regimes have been applied which seek to elicit
vascular-targeting or anti-tumor immune effects [4–7]. This
indicates that PDT could also be a rational treatment option for
non-superficial tumors such as prostate cancer and glioblastoma.
Prostate cancer is the third leading cause of cancer related
deaths for North American men [8]. The primary treatment of
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vation therapy, radiotherapy and transperineal brachytherapy. All
these treatments have a number of adverse effects which have a
considerable impact on the patients [9]. Due to the dramatic
improvements in early prostate cancer diagnosis focal treatments,
such as cryotherapy, high-intensity focused ultrasound and PDT
are emerging as new therapeutic options [10,11]. The major
drawback of focal therapy is the uncertainty of complete tumor cell
eradication, especially since little is known about the response of
tumor cells that escape from focal therapy. An unwanted scenario
is that these tumor cells gain increased malignancy or start to
secret factors that support proliferation or infiltration of residual
cancer cells in a paracrine fashion.
Glioblastoma multiforme (GBM) is the most common and most
aggressive type of primary brain tumors in humans. The median
survival time of GBM patients is 14.6 months [12]. One of the
characteristic features of glioblastomas is their diffuse infiltrative
nature [13]. Recently it was observed that fluorescence-guided
resection and repetitive PDT can significantly prolong median
survival in patients with GBM [14,15]. Furthermore, long-term
survival of GBM patients after PpIX-based PDT was reported
from other clinical studies [16,17]. Despite these promising
observations various issues have to be addressed to optimize
PDT as a therapeutic option for GBM. For example, the response
of tumor cells that survive PDT due to their advanced infiltration
into the normal brain tissue is not well defined, but could be a
target for an adjuvant therapy.
We have previously reported how the transcriptome of the
prostate cancer cell line PC-3 responds to 5-ALA-based PDT [18].
Surprisingly PC-3 cells upregulated not only stress and DNA
repair genes but also genes that code for proteins which are
involved in the regulation of immune responses including certain
chemokines and cytokines. Therefore, we wanted to know whether
or not this observation holds true for other PS, for other prostate
cancer cell lines, for tumor cells of another tissue origin and for
tumors in vivo. To this end we comparatively analyzed the genome-
wide transcriptional changes after low-level, non-lethal PDT in
two human prostate and glioblastoma cell lines each, compared
the transcriptome of the human prostate cancer line PC-3 after 5-
ALA- and photofrin-based PDT and analyzed the transcriptional
changes of murine prostate cancer cells subcutaneously trans-
planted into albino C57BL/6 mice upon PDT. We observed,
independent of the tissue origin and the type of sensitizer, a
marked transcriptional stimulation of genes coding for proin-
flammatory cytokines, which stimulate and attract predominantly
myeloid leukocytes and, at the same time, activation of genes
encoding proteins involved in cell cycle arrest. Taken together, the
unavoidable incomplete destruction of tumor tissue by PDT under
clinical settings might even support anti-tumor immune responses.
Results
Sensitization and irradiation conditions for non-lethal in
vitro PDT
In order to be able to reproducibly load tumor cells with
photosensitizer we determined the kinetics and 5-ALA concentra-
tion dependence of PpIX formation in the tumor cell lines used.
We selected two human prostate (PC-3, DU145) and two
glioblastoma cell lines (U87, U373) as well as murine prostate
carcinoma cell lines TRAMP-C1 and TRAMP-C2 which are
derived from tumors of the transgenic mouse line ‘‘transgenic
model of prostate cancer’’ (TRAMP) [19,20]. The accumulation of
photosensitizer was quantified by flow cytometry (Figure 1E). We
noted large cell line-specific differences in the levels of PpIX
formation after incubation with the PpIX precursor 5-ALA
(Figure 1A-C, E). This could be due to differences in levels of
the ATP-binding cassette transporter ABCG2 which is known to
be responsible for export of PpIX from cells [21]. Indeed, the
presence of ABCG2 mRNA in the different cell lines correlated
with low levels of PpIX after incubation with 5-ALA with the
highest amounts of ABCG2 mRNA being observed for TRAMP-
C1 and TRAMP-C2 cells which exhibited the lowest levels of
PpIX (Figure S1; Figure 1). In addition, the accumulation of PpIX
was diminished 2–3 fold when the incubation with 5-ALA was
performed in the presence of serum in the media (Figure 1B, C).
This was probably due to binding of PpIX to serum albumin once
transported out of the cell, thus shifting the PpIX steady state
levels [22,23]. Based on these data, a 16 h incubation period with
50 mg/ml 5-ALA in the presence or absence of 5% serum was
chosen for the human prostate (PC-3, DU145) and the human
glioblastoma and murine prostate cancer cell lines (U87, U373;
TRAMP-C1, TRAMP-C2), respectively. A rather low but
efficiently sensitizing photofrin concentration (5 mg/ml) was
selected to avoid possible cytotoxicity in the absence of light
(Figure 1D).
Next, light doses for irradiation of sensitized cells were defined
which would allow cell survival for a period of 24 h to 48 h during
which damaged cells could activate genes. We found that PDT
conditions which caused a reduction of activity in the cell viability
assay by 30% 24 h after PDT in comparison to a non-irradiated
cell culture rather resulted in growth arrest with little or no loss of
cells within a period of 48 h (Figure 2E). To determine the light
dose inducing a 30% reduction of cell viability by measuring
mitochondrial activity, cells were sensitized as described above and
irradiated with increasing doses of laser light. Loss of cell viability
increased with time after irradiation and light dose and differed
between cell lines. For example, a 4-fold higher light dose was
needed to induce a 30% reduction of cell viability 24 h after PDT
for DU145 cells when compared to U373 or TRAMP-C1 cells
(Figure 2A-D; Table S1). This differential sensitivity of the various
cell lines did not correlate with their capability to accumulate
PpIX in the presence of 5-ALA. Interestingly, the light doses
leading to the same 30% loss of cell viability induced a different
level of apoptosis in the analyzed human cell lines as measured by
the activation of caspase 3 and caspase 7. Whereas no or a
marginal level of apoptosis was observed in the prostate cancer cell
lines DU145 and PC-3, respectively, maximal apoptosis was
observed in the glioblastoma cell lines under the same conditions
(Figure 2F).
The transcription of a subset of chemokine and cytokine
genes is highly upregulated in tumor cells after non-
lethal in vitro PDT
To determine the genes which are deregulated 4 h and 24 h
after non-lethal PDT we performed transcriptome analysis of
irradiated and non-irradiated human and murine tumor cells
sensitized by incubation with 5-ALA (conditions are summarized
in Table S1). A large fraction of probe sets/genes upregulated after
PDT was shared between cell lines even between cell lines derived
from tumors of various tissues of origin (e.g., ,30–60% 24 h after
PDT; Table S2, Table S3). Pathway analyses using the Gene Set
Enrichment Analysis (GSEA) program revealed that 24 h after
irradiation, out of a total of 3479 gene sets, 208 gene sets were
significantly upregulated in glioblastoma cells, 156 gene sets in
prostate cancer, and 508 gene sets in the combined samples
(p,0.01) (Table S4). The sets of genes most prominently
upregulated in all cell lines belong to pathways activated by
cellular stress, including processes initiated by damage through
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21834Figure 1. Kinetics and 5-ALA concentration and serum dependency of PpIX accumulation in glioma and prostate cancer cell lines.
Tumor cells were incubated with 50 mg/ml (A, E) or with the indicated concentrations of 5-ALA (B, C) or photofrin (D) in the presence (PC-3, U373; A,
D, E and red lines in B, C) or absence of 5% serum (TRAMP-C1, TRAMP-C2; A and blue lines in B, C). Unless otherwise indicated, the PpIX content of the
cells was quantified after 16 h using flow cytometry in fluorescence channel 3 (median values 6 standard deviation). Representative histograms for 5-
ALA-treated human tumor cell lines are shown in E. Untreated cells were used as control; one representative control sample without 5-ALA
incubation is shown (red filled-in curve). The photosensitizers showed saturable accumulation depending on incubation time and concentration.
Serum in the culture medium strongly reduced ALA-based PpIX formation. The conditions for sensitizer loading used for the transcriptome analyses
are indicated by vertical dotted lines. AU, arbitrary units.
doi:10.1371/journal.pone.0021834.g001
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sets, the encoded proteins that impede proliferation (‘‘negative
regulation of cell cycle’’, ‘‘cell cycle arrest’’ and ‘‘apoptosis’’;
Table 1). Most significantly, a number of immune pathways were
transcriptionally activated by non-lethal PDT, such pathways
include ‘‘proinflammatory genes’’, ‘‘interferon-b pathway’’ and
‘‘neutrophil activation in wound healing’’ (Table 1; Figure 3). The
Gene Ontology gene sets most significantly downregulated in all
analyzed cell lines were found to be associated with mitochondrial
pathways (3 out of 5), which is in accordance with the
Figure 2. Irradiation conditions for PpIX- and photofrin-based non-lethal PDT. Human (A, B, D-F) or murine tumor cells (C) were sensitized
by incubation with 50 mg/ml of 5-ALA (DU145: 100 mg/ml) or with the indicated concentrations of photofrin for 16 h in the presence (A, D, E; F, PC-3,
DU145) or absence of 5% serum (B, C; F, U87, U373). Cells were irradiated with laser light (635 nm) delivering the indicated light doses. After the
indicated times, cell viability and caspase3/7 activation were determined and displayed either as % of control for each time point (A–D, F) or in
relative fluorescence units (RFU; E, F). Note the different propensity of prostate and glioma cells to suffer from apoptosis at low-dose PDT.
doi:10.1371/journal.pone.0021834.g002
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damage by ROS (Table S4).
Four h after non-lethal PDT, transcripts of ‘‘early response
genes’’ were among the most strongly induced and most highly
expressed genes in both human and murine tumor cells (Figure 4,
Table S2, Table S3, Figure S2A–C). This group of genes encodes
transcription factors like FBJ murine osteosarcoma viral oncogene
homolog (FOS), JUN, activating transcription factor 3 (ATF3),
early growth response 1 (EGR1) and DNA-damage-inducible
transcript 3 (DDIT3). Upregulation of these genes in turn leads to
transcription of typical stress genes like the heat shock protein
(HSP) genes and can initiate G1 arrest and apoptosis (DDIT3)
[24,25]. Indeed, inducible members of the HSP gene family,
namely heat shock 70 kDa protein 6 (HSPA6) followed in rank by
HSPA1A and HSPA1B were the most dominantly induced genes
4 h after PDT in the human tumor cell lines (Figure 4A–D). In the
murine TRAMP-C1 and TRAMP-C2 cells transcripts of the
orthologs of the latter two members were prevalent 4 h after PDT
(Figure S2B, C). The dominance of transcripts of early response
transcription factor and HSP genes was lost 24 h after PDT, which
was accompanied by increased activity of two major groups of
genes involved in opposing cellular processes. One strongly
stimulated and at high level expressed group of genes encodes
proteins which exhibit anti-proliferative, pro-apoptotic and anti-
invasive functions inducible by genotoxic stress like ROS (growth
Table 1. Selected gene sets (pathways) significantly activated
in all cell lines 24 h after non-lethal PDT.
Curated gene sets Gene Ontology gene sets
UV light response (24) (Negative) regulation of cell cycle (4)
Ionizing radiation response (3) Cell cycle arrest (2)
Hypoxia (5) Apoptosis (4)
Viral infection response (14) Immune system process
Interferon regulatory factor 4 targets (4) Immune system development
Interferon-beta pathway Myeloid cell differentiation
B lymphocyte development B cell activation
Upregulated in lymphoid stem cells
Proinflammatory genes
Neutrophil activation in wound healing
The expression of 374 gene sets from a total number of 2483 curated gene sets
and 129 from a total number of 996 Gene Ontology gene sets were found to be
significantly upregulated by GSEA analysis (P,0.01). Numbers in parentheses
indicate the number of different upregulated curated gene sets or Gene
Ontology gene sets within this subset.
doi:10.1371/journal.pone.0021834.t001
Figure 3. Non-lethal ALA-based PDT stimulates expression of neutrophil activation pathways in tumor cells. Gene set enrichment
analysis (GSEA) revealed activation of a set of genes 24 h after non-lethal PDT of all 4 prostate and glioblastoma cell lines (data are shown for PC-3)
which is also found to be characteristic for neutrophil activation during wound healing [55]. Upregulation is illustrated by the concentration of the
vertical black lines (that represent gene set member positions within the ranked gene list) at the left side of the gene list (‘‘zero cross’’; see ‘‘waterfall
plot’’ at the bottom of the graph). This distribution leads to a high and significant enrichment score (maximum deviation of the green line from zero;
P,0.001 and false discovery rate (FDR) ,0.001).
doi:10.1371/journal.pone.0021834.g003
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phosphatase 1 (DUSP1), ADAM metallopeptidase with thrombos-
pondin type 1 motif 1 (ADAMTS1), homocysteine-inducible,
endoplasmic reticulum stress-inducible ubiquitin-like domain
member 1 (HERPUD1) [26], zinc finger protein 36 (ZFP36);
growth differentiation factor 15/NSAI-activated gene 1 (GDF15/
NAG-1 [27], spermidine/spermine N1-acetyltransferase 1 (SAT-1)
[28]). The second group of genes codes for proteins which are
known or supposed to enhance cell survival after cellular stress by
inhibiting apoptosis and cell cycle arrest (brain expressed X-linked 2
(BEX2) [25]) or by supporting detoxification of harmful com-
pounds generated by ROS (aldo-keto reductase 1C1/1C2 (AKR1C1/
AKR1C2)) (Figure 4A–D).
Interestingly, among the genes highly upregulated by the tumor
cells after PDT were a number of immune response genes, notably
chemokine and cytokine genes as well as chemokine and cytokine
receptor genes (Figure 4, Figure 5). Expression of a substantial
fraction of these genes was significantly upregulated 24 h after
PDT often in both prostate and glioblastoma cell lines (P,0.05;
two-way-ANOVA test). Among the most consistently upregulated
genes were the chemokine genes CXCL2, CXCL3 and interleukin-8
(IL8)/CXCL8 as well as the cytokine gene IL6 (Figure 5A–C, H).
Upregulation of the CXCL2, CXCL3 genes was observed already
4 h after PDT in most cell lines (data not shown). Expression
analysis of the network of gene products interacting with IL6
revealed a possible autostimulatory loop in PC-3 cells involving
IL6 and its receptor subunits IL6R/IL6RA and IL6ST/IL6RB
(Figure 6). Of note, expression of CCAAT/enhancer binding protein b
(CEBPB) which encodes a transcription factor known to be
involved in regulation of expression of IL6, was 3-fold and 4.2-fold
induced 4 h and 24 h after PDT, respectively (not shown).
Furthermore, genes encoding both negative and positive regulators
of IL6 signaling namely suppressor of cytokine signaling 3
(SOCS3) and Janus kinase 1 (JAK1)/JAK2, respectively, were
upregulated. For the IL6 gene we have previously shown that
transcriptional upregulation also translates into elevated secretion
of the encoded protein by PC-3 cells after 5-ALA-based PDT [18].
No statistically significant activation was observed for some
chemokine and cytokine genes (e.g., CXCL1 (P=0.25), CCL26
(P=0.24; data not shown); IL18, Figure 5J); CXCL14 was found to
be significantly downregulated (Figure 5E). To validate the
expression data obtained by microarray oligonucleotide experi-
ments we analyzed the mRNA levels of a selected set of genes (IL6,
CXCL8 and CXCL14) in total RNA from PDT-treated and
control cells 24 h after irradiation. We found a good agreement
between the two sets of expression values determined by the two
different quantitation methods (Figure S3, Figure 5). This is
reflected by coefficients of determination R
2 close to 1.0
(0.94760.072) and a similar statistically significant up- (IL6,
CXCL8) and down-regulation (CXCL14) as found using the
oligonucleotide microarray data set.
However, there is also a fraction of genes (,25%) which was
preferentially upregulated ($4-fold) in PC-3 or U87 cell and thus
might exhibit tissue-of-origin-specific stimulation. The most
differentially stimulated genes are either already comparatively
highly expressed in the unresponsive cell line (e.g., EGR1, IL11,
AKR1C1-3 in U87; CD55 in PC-3) or probably do not belong to
the repertoire of expressible genes in the respective cell line (nuclear
receptor subfamily 4 group A member 1 (NR4A1), tumor necrosis factor-a-
induced protein 6 (TNFAIP6), dehydrogenase/reductase (SDR family)
member 9 (DHRS9), cyclin-dependent kinase inhibitor 1A (Kip2) in U87)
(Table S5).
In comparison, only few genes/probe sets were downregulated
.3-fold after PDT (Figure 4E, F and data not shown). The most
strongly expressed genes that were downregulated often encoded
cell growth and survival promoting proteins.
ROS-inducible genes are more efficiently upregulated by
5-ALA-based PDT than by photofrin-mediated PDT
Interestingly, although endogenously produced PpIX and the
synthetic oligomeric porphyrin photofrin are thought to act in
different cellular compartments [3], a similar set of genes was
upregulated both at 4 h and 24 h after non-lethal PDT in PC-3
cells (Figure 4A, B). However, despite a similar level of inhibition
of cell viability 4 h after non-lethal PDT (5-ALA 1563%;
photofrin 17.560.5%; Table 1) 14% (28/204) of the genes/probe
sets, which were more than 3-fold upregulated after 5-ALA-based
PDT, exhibited a $4-fold higher transcriptional activation in
comparison to that observed after photofrin-mediated PDT (Table
S6). The preferentially upregulated genes that were expressed at a
high level comprised, among other genes, early response genes
(FOS), HSP genes (HSPD1, HSPA6), cell survival genes (histone
cluster 1 genes), as well as immune response genes (IL1A, CCL26).
In contrast, no gene strongly expressed after PDT (.1000 RFU)
was selectively stimulated by photofrin-based PDT (Table S6).
Transcriptional upregulation of proinflammatory genes
in TRAMP-C2 tumors after non-lethal PDT
Since the expression of chemokine and cytokine genes were
consistently upregulated in cell lines after 5-ALA-based PDT in
vitro, we examined whether 5-ALA-based PDT could also induce
the expression of proinflammatory genes in tumors, which could
support anti-tumor immune reactions. We used as a tumor model
murine TRAMP-C2 prostate tumor cells grown subcutaneously in
albino C57BL/6 mice, which allowed transdermal irradiation of
the tumor with visible light. First we optimized sensitization
conditions by measuring the accumulation of PpIX in the skin
over the tumor after i.p. injection of 5-ALA as an approximation
for PpIX formation in tumor tissue. In most mice, maximal PpIX
levels in the skin were reached after 2–3 h (Figure 7A). A similar
kinetic of PpIX accumulation was observed by spectrophotometric
determination of PpIX in tumor extracts (Figure 7B).
Compared to TRAMP-C2 tumors, relative high levels of PpIX
were found in extracts of liver, seminal vesicle and skin (Figure 7C).
This might be due to the strong expression of the PPIX efflux
transporter gene Abcg2 in C2 tumors and the C2 tumor cell line
(Figure S1) and could explain the dose-limiting side effects seen in
the mice after PDT. Consequently, the light doses which could be
applied led to an inefficient control of tumor growth (Figure 7D,
E). Transcriptome analyses using RNA isolated from irradiated
and non-irradiated whole tumors 14 h and 24 h after PDT
revealed that the fraction of highly transcriptionally activated
genes after non-lethal PDT comprised mostly genes encoding
proinflammatory factors (Figure 7F; Figure S2). As observed for
PDT-treated tumor cell lines, Cxcl2, Cxcl3 and Il6 were among the
most strongly upregulated genes, although we cannot exclude that
these cytokines were expressed by stromal cells in the tumor
microenvironment or tumor-associated immune cells. Interesting-
ly, Sprr2h (small proline-rich protein 2) a gene known to be regulated by
IL6/STAT3 signaling [29] is the second most strongly induced
gene 14 h after PDT (Figure 7F). Four h after PDT, Hsp1a and
Hsp1b belonged to the group of most strongly activated and most
highly expressed genes (Figure 7F).
Discussion
Various reasons exist why non-lethal PDT is often applied
unintendedly to tumor cells in vivo. One of these reasons is that cells
Immune Mediator Induction by Non-Lethal PDT
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ability to accumulate PS as well as in their susceptibility to
oxidative stress. Indeed, we observed a striking variability of PpIX
accumulation between the different tumor cell lines used. This is
not restricted to tumor cells in vitro, but was also observed in tumor
cells in vivo [30,31]. In the present study we identified genes that
are upregulated in cancer cells upon non-lethal PDT in vitro and
compared them to genes which were affected within tumor tissues
in vivo. Importantly, we found that cancer cells independent of their
tissue origin (prostate and brain) by themselves upregulate
immune-related genes as a response to PDT-induced cell stress.
This indicates that oxidative stress induces similar responses in
different cell types, all aimed to limit the sensitivity of the cells to
ROS, to repair the inflicted cell defects and to coordinate immune
responses intended to clear the irreversibly damaged tissue from
the organism. This finding has important implications for the use
of PDT as a treatment option for both GBM and prostate cancer:
(I) our results indicate that the overall response of different tumors
to non-lethal PDT is similar between tumors originating from
different tissue types; (II) tumor cells respond to non-lethal PDT by
upregulating the expression of immune function genes which may
support proinflammatory anti-tumoral immune responses; (III)
PDT could be especially suitable for immunogenic tumors where
the benefit from tumor immunity for the patient is larger than the
possible disadvantage caused by a higher concentration of tumor
growth-promoting factors associated with inflammation.
Early transcriptional changes elicited by non-lethal PDT
mirrored the changes previously observed using various PS and
PDT high-dose settings [32–36]. Early response genes, stress genes/
heat shock protein genes, growth arrest/DNA damage response/
Figure 5. Transcription of genes encoding inflammatory interleukins and chemokines is enhanced after non-lethal PDT in tumor
cell lines. Tumor cells were subjected to non-lethal PDT after sensitization with 5-ALA or photofrin and RNA was analyzed after 24 h recovery from
PDT by hybridization to oligonucleotide microarrays as described in Legend to Figure 4. Mean expression values in relative fluorescence units (RFU)
and their deviations for expressed interleukin and chemokine and interleukin and chemokine receptor genes are shown. For the CXCL8 and CXCL14
genes the 202859_x_at and 222484_s_at probe sets were used, respectively. For PC-3 and U87 samples mean expression values from duplicates, for
DU145 and U373 samples single measurements were used. Significance levels (P) were calculated using Two-way ANOVA.
doi:10.1371/journal.pone.0021834.g005
Figure 4. Genes transcriptionally deregulated in glioma and prostate cancer cell lines after non-lethal PDT. Tumor cells were subjected
to non-lethal PDT after sensitization with 5-ALA (A, C–F) or photofrin (B). Total RNA was isolated 4 and 24 h after PDT and analyzed by hybridization
to oligonucleotide microarrays. After normalization, fold change of gene expression between corresponding irradiated and non-irridiated samples
was calculated and plotted against the expression level after PDT. Only genes (‘‘probe sets’’) are shown which were up- and down-regulated $3-fold
and for which a ’’present call‘‘ was registered for all irradiated and non-irradiated samples, respectively. The most strongly up-or down-regulated and
most highly expressed genes in the samples are identified by gene symbols. Multiple depiction of gene symbols result from the presence of multiple
probe sets for individual genes. Genes encoding immune modulatory proteins are additionally marked with small circles. Note that the latter genes
are among the most strongly upregulated genes. A color code was used to discriminate groups of genes encoding functionally related proteins (see
boxed Figure legend). For all samples mean expression values from duplicates were used. FU, fluorescence units.
doi:10.1371/journal.pone.0021834.g004
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poptotic/proangiogenetic genes were already upregulated 4 h after
non-lethal PDT (Table S2). Of note after 24 h a few unique genes
wereupregulated not seen uponhigh-dose PDT, due to the fact that
most if not all tumor cells did not survive high-dose PDT for 24 h.
Among these genes were immune response genes, including IL1A,
IL6, CXCL2, CXCL3 and CXCL8/IL8, some of which appeared to
be preferentially upregulated by PpIX, rather than by photofrin-
mediated PDT (Table S6). All these genes have effects on the
recruitment and/or activation of granulocytes. It is conceivable that
due the different location of the PS within cell compartments and
the short half-life of ROS generated by PS activation resulting in
localized damage of different cell compartments similar but not
identicalgene activation programsareinitiated.Thiscould also lead
to differential activation of cellular damage repair programs
associated with increased resistance to PDT. Resistance to
photofrin-based PDT in U87 cells was recently reported to be
caused by stimulation of expression of ALKBH2 (alkylated DNA
repair protein alkB homolog 2 gene) [37]. However, 5-ALA-based
PDT with U87 cells did not activate this repair process in our
experiments (data not shown). Therefore, PpIX PDT might
combine two advantages by inducing immune mediators more
efficiently and at the same time being less prone to activate repair
processes. Buytaert and colleagues recently investigated the
transcriptional changes in bladder cancer cells upon hypericin-
mediated low-dose PDT and observed upregulation of the
granulocyte-macrophage colony-stimulating factor (CSF2) and TLR2 genes
besides IL8 [38]. Whether this difference is due to the use of
hypericin as PS,the different time point of measurementsafter PDT
or the differentcelllinesanalyzed is currently unknown.In addition,
the clear upregulation of the matrix metalloproteinase-1 (MMP1),
MMP10 and MMP13 genes reported by these authors was not seen
in our experiments. This result is unexpected, since the upregulated
transcription factors and stress response genes were similar in both
studies. It could well be that different cell types, in addition to
commonly upregulated genes, have an individual repertoire of
genes whichthey canexpress followingPDT. Indeed, we observed a
cell type-specific upregulation of a number of genes such as
AKR1C1-3, CD55, IL11, TNFAIP6 and others in our investigation.
Whatever the reasons for the different findings, it reminds us to be
cautious assessing the potential impact of the transcriptional
changes after PDT on tumor cell behavior. Indeed, there are other
reports suggesting that photofrin-mediated PDT using subthera-
peutic light doses can promote growth and infiltration of GBM
[39,40]. However, there is increasing evidence from clinical data
that suggests that GBM patients can benefit from PpIX-based PDT
bysignificantly longermediansurvival [14,15].More importantly,it
was reported that there are long-term survivors within the cohort of
patients that were treated with PDT [16,17,41]. Indeed, when we
analyzed changes in the transcriptome of TRAMP-C2 tumors in
vivo, we noticed a robust upregulation of immune response genes,
including Il6, Cxcl2 and Cxcl3 within the tumors (Figure 7F).
Whetherthis upregulationofexpressiontakesplaceintumorcellsor
cells of the tumor microenvironment was not determined. However,
since the same immune mediators were upregulated by prostate and
glioblastomacelllinesin vitro, this suggests that tumorcellscooperate
inattracting granulocytes to theregion ofPDT. Indeed, granulocyte
infiltration was observed in tumors treated with non-lethal PDT by
us (data not shown) and others [42,43]. It has been suggested that
induction of immune related genes in tumor cells upon PDT is due
to NF-kB activation [44]. Among the hundreds of NF-kB target
genes, some may also favor tumor cell growth and dissemination.
Especially, the prostaglandin endoperoxide synthase 2 gene (PTGS2/COX-
2) and matrix metalloproteinase genes are important in this context.
They were, however, not found to be upregulated more than three
fold in our experimental system. On the other hand, some tumors
have acquired the ability to use the IL6/IL6 receptor (IL6R)/signal
transducer and activator of transcription 3 (STAT3)/hypoxia-
inducible factor 1a (HIF1a) signaling cascade to be able to
proliferate faster [45,46]. We have observed that expression of
IL6 as well as IL6R is significantly upregulated in both prostate and
glioblastoma cancer cells by PDT. Furthermore, IL6ST, the shared
Figure 6. Transcriptional changes observed for genes encoding IL6-interacting proteins in PC-3 cells after PpIX-mediated PDT. The
changes of gene expression 4 h and 24 h after PDT measured by oligonucleotide microarray analyses are depicted as fold change (fluorescence of
irradiated/non-irradiated sample). The magnitude of fold change is indicated by different colors (,1.2-fold, white; $1.2-fold, ,2-fold, orange;
$2-fold, red). The strongest upregulation of expression was observed for the IL6 gene (12.3-fold) which could part of an autostimulatory loop with
the also upregulated IL6 receptor subunits (IL6R and IL6ST). The size of the ovals indicates the absolute expression level after PDT (,100 FU, small
symbol; $100, ,1000, medium symbol; $1000, large symbol). The lines between the ovals symbolize various types of interaction between the
proteins or genes.
doi:10.1371/journal.pone.0021834.g006
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gene is also upregulated 24 h after PDT. Hence the elevated level of
IL6 in the tumor microenvironment, besides exerting an immune
stimulatory effect, may also support tumor growth and thereby limit
the benefit gained by anti-tumor immune responses [47].
Interestingly, in both prostate cancer and GBM the IL6-STAT3
axis is thought to play a tumor-promoting role [45,48]. Disruption
of this novel autocrine loop (IL6/STAT3/HIF1a) with appropriate
drugs may enhance the therapeutic effect of PDT [49]. Indeed,
clinical trials are underway where the impact of IL6-targeting
antibodies on prostate cancer and other tumors is being evaluated
(www.clinicaltrials.gov).
Taken together, our results suggest that non-lethal PDT
supports anti-tumor immune responses and, therefore, PDT seems
to be a suitable therapy, especially for immunogenic tumors, even
if a complete eradication of tumor cells by phototoxicity alone is
not guaranteed. Further elucidation of tumor-specific and PS-
selective variations of the transcriptional response after PDT is
desirable to minimize the risk of harmful adverse effects through
induced autocrine tumor-promoting loops.
Figure 7. Transcription of genes encoding inflammatory interleukins and chemokines is enhanced after non-lethal PDT in murine
C2 tumors. The kinetics of PpIX accumulation in mouse tissues after i.p. injection of 5-ALA was determined either by direct measurement of PpIX
fluorescence in the skin covering the tumor (A) or by fluorescence spectroscopical determination of PpIX in tumor extracts from a single mouse each
which was sacrificed at the indicated time (B). PpIX accumulation in different tissues relative to TRAMP-C2 tumors 3.5 h after 5-ALA injection is shown
in (C). In (A), a typical kinetic of PpIX accumulation in skin is shown. Maximal accumulation of PpIX in skin and tumor tissue was observed ,180 min
after 5-ALA injection. Tumors were subjected to PDT (75 J/cm
2) after sensitization with 5-ALA for 180 min. Note, that 5-ALA-mediated PDT after
maximal sensitization had only a marginal (D) or transient inhibitory effect on tumor growth (E) even after duplicate application one week apart. For
transcriptome analysis, sensitized tumors from a single mouse each were treated or not with laser light (635 nm; 75 J/cm
2), excised 4, 14 or 24 h after
irradiation. RNA was isolated and analyzed by hybridization to oligonucleotide microarrays. After normalization, fold change of gene expression
between irradiated and non-irridiated samples was calculated and plotted against the expression level after PDT (F). Only genes (‘‘probe sets’’) are
shown which were upregulated $3-fold and for which a ’’present call‘‘ was registered in the irradiated sample. The most strongly upregulated and
most highly expressed genes in the samples are identified by gene symbols. Multiple depiction of gene symbols result from the presence of multiple
probe sets for individual genes. Genes encoding immune modulatory proteins are additionally marked with small circles. AFU; arbitrary fluorescence
units; n, number of mice tested.
doi:10.1371/journal.pone.0021834.g007
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Ethics Statement
Animal studies were approved by the local regulatory agency
(Regierung von Oberbayern, Munich, Germany; approval ID
55.2-1-54-2531-109-06).
Cell lines and cell culture
Human prostate carcinoma cell lines PC-3 and DU145 (DMSZ,
German Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany), and the human glioblastoma cell lines
U87 MG (Institut fu ¨r angewandte Zellkultur, Dr. Toni Lindl
GmbH, Mu ¨nchen, Germany) and U373 MG (ATCC) as well as
murine prostate carcinoma cell lines TRAMP-C1 and TRAMP-
C2 (LGC Standards GmbH, Wesel, Germany) were cultured in
RPMI-1640 medium supplemented with 5% fetal calf serum (FCS
‘‘Gold’’; PAA Laboratories, Coelbe, Germany), 2 mM L-gluta-
mine, 100 U/ml penicillin, 100 mg/ml streptomycin, non-essential
amino acids and 1 mM sodium pyruvate (GIBCO/Invitrogen,
Karlsruhe, Germany) at 37uC with 5% CO2 in a humidified
atmosphere. Absence of mycoplasma contamination war deter-
mined using the VenorGeM Kit (Minerva Biolabs, Berlin,
Germany).
Optimization of photosensitizer generation and loading
Tumor cells (6610
4 per well) were plated in 24-well plates
(Nunc GmbH, Wiesbaden, Germany) and grown over night in the
presence of 5% FCS. Cells were washed with FCS free medium
and incubated with varying 5-ALA concentrations (Medac
GmbH, Hamburg, Germany) in the presence or absence of 5%
serum for the indicated times. 5-ALA stock solutions (1 mg/ml)
were freshly prepared in serum free medium. Photofrin (Axam
Pharma International BV, Quebec, Canada) sensitization of cells
was measured in the presence of 5% FCS. Photofrin stock
solutions (3.75 mg/ml in 0.9% NaCl solution) were stored at 4uC
in the dark. Cells were removed by treatment with 200 mlo f
0.05% trypsin/0.53 mM EDTA (Invitrogen, Paisley, UK), spun
down at 500 x g for 5 min after addition of 1 ml of 5% FCS-
containing medium and resuspended in 200 ml of Hank’s balanced
salt solution. PpIX and photofrin fluorescence was induced by a
635 nm red diode laser and measured in the FL3 photomultiplier
tube (670 nm long pass filter) of a FACSCalibur flow cytometer
(BD Biosciences, Erembodegem, Belgium) and its median was
used after subtraction of the median of the fluorescence of
unlabeled cells as a measure of the PpIX or photofrin content in
the tumor cells. To exclude underestimation of the PPIX
concentrations by FACS measurements due to quenching at
relatively high intracellular PPIX levels control experiments using
quantitation of PPIX by fluorescence spectrometry after extraction
from cells and dilution were performed. Both methods proved to
be equivalent (Figure S4). In all experiments with sensitized cells,
care was taken to minimize exposure of the cells to ambient light.
In vitro PDT treatment
For determination of the light dose suitable for induction of a
,20% and ,30% loss of cell viability 4 h and 24 h after PDT,
respectively, 1610
4 cells per well were plated in flat bottom 96-
well plates (Nunc GmbH, Wiesbaden, Germany) in 4–6 replicates
per data point and grown for 6–8 h in medium with 5% FCS.
Sensitization of the cells with 2.5–10 mg/ml photofrin or 10–
200 mg/ml 5-ALA was performed for 16 h in 100 ml of fresh
medium with (PC3, DU145) or without (U87, U373) 5% FCS.
The medium was replaced with 100 ml of RPMI-1640 without
phenol red (Invitrogen/Gibco) containing supplements and 5%
serum as listed above. Specific light doses were delivered to the
cells by irradiation (six wells at the time) with laser light (600 mm
fiber with attached microlens, Biolitec AG, Jena, Germany and a
635 nm Ceralas diode laser, CeramOptec GmbH, Bonn,
Germany) at 100 mW/cm
2 for varying times in a light tight box
with a 37uC warm plate. Because of higher light sensitivity of
photofrin-sensitized cells, irradiation with different light doses was
performed on separate microtiter plates to exclude effects from
scattered light on cells in neighboring wells. For the isolation of
RNA from PDT-treated cells, tumor cells (1610
6) were grown in
4 ml medium in 6 cm diameter cell culture dishes (Nunc),
sensitized as above with 50 mg/ml 5-ALA (DU145: 100 mg/ml)
or 5 mg/ml photofrin and irradiated at room temperature. The
following light doses (J/cm
2) were used: PC-3: 1.5 and 3; DU145:
2; U87: 1; U373: 0.5; TRAMP-C1: 0.5; TRAMP-C2: 0.8.
Separate identically treated cell cultures were used for cell viability
determination (see below). After PDT, cells were incubated in the
same medium at 37uC for the indicated times.
PDT of murine tumors
Tumors were induced by subcutaneous injection of 1-3610
6
TRAMP-C2 tumor cells in 50 ml of phosphate-buffered saline
(PBS) in the lumbar region of syngeneic male albino C57BL/6
mice (C57BL/6-Tyr
c-2J). The mice were kindly provided by H.
Schrewe (Max-Planck Institute for Molecular Genetics, Berlin,
Germany). The size of tumors was determined twice a week with a
caliper and the approximate volume was calculated by using the
formula: length x width
2/2. Tumors-bearing mice (tumor volume:
100–300 mm
3) were injected with 15 mg 5-ALA/ml PBS
(500 mg/kg) under isoflurane anesthesia. During sensitization
and a period of 3 days following PDT mice were kept in the dark.
The 5-ALA solution was freshly prepared before each experiment,
neutralized using 10 N NaOH and stored in the dark on ice. PpIX
accumulation in the skin covering the tumor was determined by
measuring the fluorescence intensity at 635 nm using an
irradiation/detection system consisting of a laser diode with an
emission wavelength of 405 nm, a bifurcated fiber (Light Guide
Optics, Rheinbach, Germany), a filter (GG435, Schott AG,
Mainz, Germany) and a fiber spectrophotometer (S2000 Mikro-
pack, Ocean Optics, Ostfildern, Germany). PpIX formation in
tumor and in other tissues as well as for comparison in PC-3 cells
was also determined by fluorescence spectroscopy after extraction
from shock-frozen tissues or cells protected from light and stored at
280uC as described recently [30]. For the calculation of the molar
PpIX concentration a tissue density of 1 g/cm
3 was assumed.
Three to 4 h after injection of 5-ALA, tumor-bearing mice were
narcotized with xylazine/ketamine, shaven at their back and
irradiated after application of a tight fitting aperture plate cut from
black cardboard. The whole tumor area was irradiated perpen-
dicular through the intact skin using the same laser light source as
described for in vitro PDT, however, applying 75 or 100 J/cm
2 at
200 mW/cm
2. After treatment, tumors were either excised, shock-
frozen and stored at 280uC or their growth was followed as
described above.
Measurement of cell viability, apoptosis and survival
After PDT, cell viability was quantified using the CellTiter-
Blue
TM Cell Viability Assay (Promega, Mannheim, Germany),
apoptosis was measured using the Apo-ONEH Homogeneous
Caspase-3/7 Assay (Promega) as recommended by the manufac-
turer. In brief, after the indicated times 200 ml of CellTiter-Blue
TM
or 100 ml Apo-ONEH solution per ml were directly added to the
cell culture medium without phenol red, mixed gently and after
1 h, samples in 96-well plates were measured directly or 1 ml of
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4uC (up to 24 h). Fluorescence was quantified in 96-well cell
culture plates (100 ml per well) in a FLUOstar OPTIMA
microplate reader (BMG LABTECH, Jena, Germany) using an
excitation/emission filter of 560/590 and 485/520 nm for the Cell
Titer Blue
TM and Apo-ONEH assay, respectively. The background
fluorescence values were obtained by addition of CellTiter-Blue
TM
or Apo-ONEH solution to medium without cells and incubation
for 1 h.
RNA labeling and oligonucleotide microarray
hybridization
PDT-treated cells or cells identically treated except for
irradiation were detached with 1 ml of trypsin/EDTA, washed
as above and stored at 280uC. Total RNA was isolated from the
cell pellets or tumors using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). The RNA yield was quantified photometrically and the
integrity was determined by capillary electrophoresis (Agilent 2100
Bioanalyzer and RNA 6000 Pico Kit; Agilent Technologies
Deutschland, Bo ¨blingen, Germany). The RNA integrity number
(RIN) provided by the Agilent system allows a quantitative
estimate of the RNA quality. The RIN number (10 represents
intact RNA) for all samples was .9.5 [50]. RNA amplification and
biotin labeling was performed by reverse transcription of 1–5 mgo f
total RNA with an oligo-dT-T7 promoter primer and linear in vitro
transcription using a kit from Affymetrix (One Cycle Target
Labeling Kit) according to the manufacturer’s instructions.
Hybridization of biotin-labeled RNA to Affymetrix Gene Chip
U133 Plus 2.0 or Mouse Genome 430 2.0 oligonucleotide arrays
was done for 16 h at 37uC in a hybridization oven (Affymetrix).
Then, the arrays were washed according to the standard protocol
and stained by addition of streptavidin-phycoerythrin using the
Fluidics Station 450 (Affymetrix). Laser scanning of the arrays was
performed using the GeneChipH Scanner 3000 7G (Affymetrix).
Raw hybridization data (probe cell intensity) were stored as CEL
files. The CEL files and normalized microarray data from this
study are MIAME compliant and are available at the ArrayEx-
press Archive (accession numbers: E-MEXP-3016 [murine cells, 8
arrays], E-MEXP-3017 [murine tumors, 7 arrays] and E-MEXP-
3020 [human cells, 32 arrays]). The Expression Console
TM 1.1
Software (Affymetrix) was used for initial data quality control and
calculation of the detection call (transcript ‘‘absent’’ or ‘‘present’’).
Microarray data analysis
CEL file data were used to determine a model-based expression
index (MBEI) with the approach of Li and Wong that is
implemented in the dChip 2009 software (http://www.dchip.
org; Dana-Farber Cancer Center and Harvard School of Public
Health, Boston, MA, USA) [51]. This algorithm has shown good
performance in processing of raw microarray data in a
comparative study of seven methods [52]. The MBEI values were
used for subsequent high-level analysis (e.g., hierarchical cluster-
ing). In addition, for the identification of pathways with
significantly changed expression between sample groups Gene
Set Enrichment Analysis (GSEA 2.0; Broad Institute, Harvard/
MIT; software available from http://www.broadinstitute.org/
gsea) was used [53]. The GSEA algorithm can identify subtle,
but significant and biologically relevant expression changes of
functionally coupled genes between two sample groups. GSEA
uses a database with .6000 gene sets (MSigDB v3.0, molecular
signature database, Broad Institute, Harvard/MIT). A gene set
consists of genes that belong to the same pathway (e.g., signal
transduction, metabolism) or that have other features in common
(e.g., chromosomal localization). For this study, only curated gene
sets (from published studies) and Gene Ontology terms with 15–
500 genes were used, leaving 3479 gene sets (2483 curated and 996
from Gene Ontology) for analysis.
Brief description of the GSEA algorithm: First, all genes are
ranked according to their signal-to-noise ratio [(m1–m2)/(s1+s2);
m, mean; s, standard deviation] between the two phenotype
groups (e.g., 24 h after irradiation without/with prior sensitiza-
tion). Then, every gene set is tested for significant functional
enrichment of its genes. The algorithm goes through the ranked
gene list, and a running-sum statistic is increased when a gene is
part of the gene set, and decreased if it is not. The magnitude of
the increment depends on the correlation of the gene with the
phenotype. The enrichment score is the maximum deviation from
zero encountered in walking the list. The enrichment score is near
0 if the genes of a gene set are distributed equally over the ranked
gene list. In case of functional enrichment, many genes are
‘‘concentrated’’ at one end of the ranked gene list because their
expression correlates with one phenotype and the enrichment
score is different from 0 (positive or negative). Permutation tests
are performed to calculate a p value and the false discovery rate
(FDR) for each gene set.
Visualization of gene expression changes in pathways was
performed using the software Cytoscape 2.7.0 ([54]; software
available at http://www.cytoscape.org) and interaction data sets
from Pathway Commons (http://www.pathwaycommons.org,
built and maintained by Memorial Sloan-Kettering Cancer
Center, New York and the University of Toronto). Network
nodes (genes) were color-coded according to their expression fold
change between nonsensitzed and sensitized samples 4 h and 24 h
after irradiation.
Quantitative RT-PCR
One mg of total RNA was reverse transcribed using the Reverse
Transcription System from Promega according to the manufac-
turer’s protocol. PCR amplification was performed using 40 ng of
cDNA, specificity-tested primers (LightCycler
TM Primer Sets;
Search LC, Heidelberg) and the LightCycler
TM FastStart DNA
MasterPLUS Sybr Green I kit (Roche, Penzberg, Germany). The
relative abundance of transcripts was calculated in arbitrary units
(AU) using the formula 2
2Cp610
10 (AU) whereby Cp represents
the crossing point where a fluorescence value of 1 is reached.
Statistics
Significance levels (P) were calculated using Two-way ANOVA
in the GraphPad Prism3 software package. Comparisons of
samples exhibiting P values ,0.05 were considered to be
significantly different.
Supporting Information
Figure S1 ABCG2 mRNA levels in human and murine
prostate tumor cell lines negatively correlate with PpIX
accumulation. The amount of ABCG2 mRNA was determined
by oligonucleotide microarray analyses in human (PC-3) and
murine prostate cancer cell lines (TRAMP-C1, TRAMP-C2) as
well as in subcutaneously grown murine prostate tumors
(TRAMP-C2). As a control, the expression of the house keeping
gene encoding the TATA-box-binding protein (TBP) is show.
Note the high levels of expression of the PpIX exporter ABCG2 in
murine prostate cancer cells which inversely correlates with their
ability to accumulate PpIX in the presence of 5-ALA (see Fig. 1A,
C; Fig. 6B, C). Mean and (standard) deviations are shown. n=2
for murine cells, n=3 for PC-3.
(PPT)
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man glioma (A) and murine prostate cancer cells (B, C)
and tumors after non-lethal PDT (D). Tumor cells and
tumors were subjected to non-lethal PDT after sensitization with 5-
ALA. Tumors were irradiated with a light dose of 75 or 100 J/cm2.
Total RNA was isolated 4 and 24 h after PDT and analyzed by
hybridization to oligonucleotide microarrays. After normalization,
fold change of gene expression between corresponding irradiated
and non-irridiated samples was calculated and plotted against the
expression level afterPDT. Only genes (probe sets) areshown which
were up- and down-regulated $3-fold and for which a ’’present
call‘‘ was registered for all irradiated and non-irradiated samples,
respectively. The most strongly up- or down-regulated and most
highly expressed genes in the samples are identified by gene
symbols. Multiple depiction of gene symbols result from the
presence ofmultiple probesets forindividual genes.Genesencoding
immune modulatory proteins are additionally marked with small
circles. A color code was used to discriminate groups of genes
encoding functionally related proteins (see boxed Figure legend).
FU, fluorescence units.
(PPT)
Figure S3 Validation of expression of selected cytokine
genes by quantitative RT-PCR. Total RNA was isolated from
glioblastoma and prostate cancer cells (DU145, n=1; all other cell
lines n=2) 24 h after photofrin (PC-3) or 5-ALA-based PDT
(conditions are summarized in Table S1). Control cells were also
incubated with photofrin or 5-ALA, however, were not irradiated.
The relative cDNA level of IL6 (A), CXCL8 (B) and CXCL14 (C)
were determined by quantitative RT-PCR. The thus determined
cDNA levels were correlated with the levels estimated from
oligonucleotide microarray experiments shown in Fig. 5. A high
degree of agreement between the two different quantitation
methods was noted (coefficient of determination
R2=0.94760.072). Significance levels (P) were calculated using
two-way ANOVA.
(PPT)
Figure S4 Equivalence of PPIX quantitation in PC-3
cells by flow cytometry or extraction and photometric
measurement. 36105 cells were incubated for 16 h with
different 5-ALA concentrations in the presence of 10% FCS.
PPIX content was either determined after extraction of the cell
pellets with 100 ml the aqueous based solubilizer Solvable
TM
(PerkinElmer) and further 100-fold dilution with Solvable
TM by
fluorescence spectroscopy (A) or by flow cytometry (FL3 photo-
multiplier tube; 670 nm long pass filter) (B). The concentrations of
the final dilutions were calculated from a standard curve obtained
by dilution of purified PPIX in Solvable
TM. The median of the
PPIX fluorescence of the strongest labeled cell fraction is
indicated. Both measurements proved to be highly equivalent as
demonstrated by a coefficient of determination (R2) close to 1 (C).
(PPT)
Table S1 Non-lethal PDT conditions for transcriptome
analysis of human and murine prostate and glioblasto-
ma cell lines.
(DOC)
Table S2 Genes upregulated in both prostate cancer
PC-3 and glioblastoma U87 cells 4 h and 24 h after non-
lethal 5-ALA-based PDT.
(XLS)
Table S3 Genes upregulated in both glioblastoma U87
and U373 cells 24 h after non-lethal 5-ALA-based PDT.
(XLS)
Table S4 Significantly deregulated gene sets (pathways)
in prostate and glioblastoma tumor cell lines 24 h after
PDT.
(DOC)
Table S5 Genes preferentially upregulated in prostate
cancer PC-3 cells or in glioblastoma U87 cells 24 h after
non-lethal 5-ALA-based PDT.
(XLS)
Table S6 Genes preferentially upregulated 4 h and 24 h
after non-lethal 5-ALA- versus photofrin-based PDT in
PC-3 cells.
(XLS)
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